Anjie Biomedical Technology

Main focus: Next generation CAR-T cells

Company stage: Clinical

Diseases: Solid tumours

Genome editing tool: CRISPR-Cas9

Funding stage: Private

Location: Guanzhou, China

Anjie Biomedical Technology develops next generation CAR-T cells for solid tumour treatment. The company uses CRISPR to knock out PD-1 from its CAR-T cell products, in order to optimise efficacy and safety.

Anjie Biomedical Technology Co., Ltd

Press Releases

Related News and Updates

Job Opportunities

Clinical Trials

Pre-clinical Trials

Stocks and Markets

Diseases

Webinar

Your Latest CMN News

CMN Weekly (21 February 2025) - Your Weekly CRISPR...

CMN Weekly

Feb. 21, 2025

Some of the best links we picked up around the internet

Bahrain Reports First Administration of CASGEVY in...

Feb. 19, 2025

The Bahrain Oncology Centre announced a major milestone on Sunday with the successful administration of CASGEVY - the world's only approved therapy...

CRISPR–Csm enables single-molecule RNA imaging in...

CMN Briefs

Feb. 18, 2025

A new technique developed by Jennifer Doudna and colleagues at the University of California, Berkeley, achieves single-molecule resolution imaging of...

CRISPR screen links BAF mutation to premature...

CMN Briefs

Feb. 17, 2025

A genome-wide CRISPR screen in fibroblasts from patients with Néstor-Guillermo Progeria Syndrome (NGPS) identified 43 genes that mitigate multiple...

CMN Weekly (14 February 2025) - Your Weekly CRISPR...

CMN Weekly

Feb. 14, 2025

Some of the best links we picked up around the internet

FDA Grants Dual Designations to Arbor's Gene...

CMN Clinical

Feb. 12, 2025

The FDA has granted orphan drug and rare pediatric disease designations to Arbor Biotechnologies' ABO-101, a gene-editing therapeutic candidate for...